(Q37107485)

18 August 2017

1 reference

title

The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment (English)

1 reference

18 August 2017

1 reference

M Andrikoula

1

1 reference

18 August 2017

I F W McDowell

series ordinal

2

1 reference

18 August 2017

publication date

1 April 2008

1 reference

Diabetes, Obesity and Metabolism

18 August 2017

published in

1 reference

18 August 2017

volume

10

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

271-278

1 reference

Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Atherogenicity of triglyceride-rich lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Remnant lipoproteins as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Hypertriglyceridemia as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

LDL size and risk of coronary heart disease in elderly men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Relationships of apolipoprotein B(100) with the metabolic syndrome in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

The Friedewald formula underestimates LDL cholesterol at low concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Measurement issues related to lipoprotein heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Apolipoprotein concentrations during treatment and recurrent coronary artery disease events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00714.X

10.1111/J.1463-1326.2007.00714.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference